New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:28 EDTHSH, JKS, FRO, ARO, SDRL, BCRX, PFE, AZN, PF, PPC, SPLSOn The Fly: Pre-market Movers
HIGHER: Pilgrim's Pride (PPC), up 5% after proposing to acquire Hillshire Brands (HSH) for $45.00 per share cash. Hillshire up 21% following the news, while Pinnacle Foods (PF), which has agreed to be acquired by Hillshire, is down 6.4%... BioCryst (BCRX), up 19% after announcing "positive" results from OPuS-1, a trial of BCX4161... Seadrill (SDRL), up 2.6% after signing investment and cooperation pact with Rosneft and North Atlantic... Aeropostale (ARO), up 11% after $150M financing transaction with Sycamore. LOWER: AstraZeneca (AZN), down 1.7% after downgraded at Societe Generale following Pfizer (PFE) confirming it won't bid for AstraZeneca after rejection of proposal. Pfizer shares are up 1% after the news... Staples (SPLS), down 1% after downgraded at Goldman... Frontline (FRO), down 7.4% after saying it sees weaker Q2 operational results... JinkoSolar (JKS), down 7.8% after reporting lower than expected Q1 earnings results.
News For HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 13, 2014
07:01 EDTJKSJinkoSolar to supply 21.5MW of PV solar modules for Searchlight solar projects
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 12, 2014
19:26 EDTBCRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTBCRXCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTBCRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTBCRXTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTBCRXMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
October 9, 2014
14:55 EDTBCRXHospital says deputy showing no signs of Ebola, AP reports
Subscribe for More Information
14:24 EDTBCRXCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTBCRXFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTBCRXLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
09:41 EDTARO, SPLSBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
08:10 EDTAZNAstraZeneca reports Phase IIb study of benralizumab met primary endpoint
Subscribe for More Information
October 8, 2014
11:22 EDTBCRXChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
10:55 EDTPFELeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:19 EDTPFECBI to hold a conference
Subscribe for More Information
07:18 EDTPFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:11 EDTBCRXEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use